Abstract: Provided is a novel compound having rapid and long-lasting therapeutic effects on diseases exhibiting depressive symptoms. Specifically, provided are an agent for prevention and/or treatment of a depressive symptom, consisting of R(?)-ketamine or a pharmacologically acceptable salt thereof, and a pharmaceutical composition for prevention and/or treatment of a depressive symptom, comprising R(?)-ketamine or a pharmacologically acceptable salt thereof in an effective amount for reducing a depressive symptom, and being substantially free of S(+)-ketamine, and a pharmacologically acceptable salt thereof.

Abstract: Provided is a novel compound having rapid and long-lasting therapeutic effects on diseases exhibiting depressive symptoms. Specifically, provided are an agent for prevention and/or treatment of a depressive symptom, consisting of R(?)-ketamine or a pharmacologically acceptable salt thereof, and a pharmaceutical composition for prevention and/or treatment of a depressive symptom, comprising R(?)-ketamine or a pharmacologically acceptable salt thereof in an effective amount for reducing a depressive symptom, and being substantially free of S(+)-ketamine, and a pharmacologically acceptable salt thereof.

Abstract: Provided is a method for quantifying vitamin D, with the vitamin D contained in a biological sample being derivatized with a derivatization reagent and being measured with a mass spectrometer, the method including, a derivatization step of derivatizing n number of samples by using n types of 4-(4?-dimethylaminophenyl)-1,2,4-triazoline-3,5-dione (DAPTAD) isotopologues respectively as derivatization reagents, a mixing step of mixing the n types of derivatization samples obtained in the derivatization step, and a quantitative analysis step of subjecting each of the n types of vitamin D derivatives contained in the mixed sample obtained in the mixing step to quantitative analysis using a mass spectrometer.

Abstract: The present invention provides a method for acquiring data relating to the onset of cerebral infarction, characterized in that the method includes determining the level of an antibody to DIDO1 protein or a portion thereof, and/or the level of an antibody to CPSF2 protein or a portion thereof, the antibody or antibodies being present in a body fluid sample collected from a living body. The invention also provides a kit for acquiring data for carrying out the method of the present invention. The invention can accurately discern signs linked to the onset of cerebral infarction.

Abstract: Described are: [1] a compound or the like represented by the formula (1); [2] a compound or the like having a target molecule recognition element bound to the compound or the like described in the above [1]; and [3] a metal complex compound or the like having a metal selected from the group consisting of a radioactive metal and a radioactive atom-labeled metal, and the compound or the like described in the above [1] or [2] coordinated to the metal. Also described are uses of the compound or the like described in the above [1] or [2] or the metal complex compound or the like described in the above [3] in a radioactive drug, a radiotherapeutic agent or a radioactive diagnostic imaging agent.

Abstract: The purpose of the present invention is to provide a composition containing, as an active ingredient, a substance having rich history of use in foods or an ingestion experience in human and having an effect of inhibiting Fc?RI expression on a pDC. This purpose can be achieved by a composition for activating plasmacytoid dendritic cell comprising: at least one active ingredient selected from the group consisting of a bacterial cell, a bacterial component, and a culture of Pediococcus lactic acid bacteria, and a product obtained by treating any one of them, and having an effect of inhibiting Fc?RI expression on a plasmacytoid dendritic cell.

Abstract: The objective of the present invention is to provide a particle detection device and a particle detection method that can individually and continuously detect a wide range of particles. The objective is achieved by a particle detection device including: a particle separation channel through which particles are separated according to particle sizes in a perpendicular direction to the flow of fluid; and two or more particle recovery channels that are connected to and branched from the particle separation channel, in which each of the particle recovery channels includes a particle detection unit that includes an aperture and an electric detector.

Abstract: Provided are a functional microbial material and a method for producing a fermentation product, wherein the functional microbial material and the fermentation product are environment-friendly and improve the quality of crops. The present invention relates to a microbial material and a method for producing a fermentation product wherein the microbial material and the fermentation product are obtained by fermentation of a fermentation raw material including a plant-derived raw material and an animal-derived raw material using a population of microorganisms including a plurality of species of thermophilic microorganisms, and lead to a remedy for soil and water pollution and to the inhibition of greenhouse gas generation, as well as contribute to improvements in the functionality of plants, particularly the expression of genes involved in biophylaxis and resistant to high-temperature disorder, and an increase in antioxidant components.

Abstract: The present invention aims to obtain an anti-repulsive guidance molecule a (RGMa) antibody having a high binding activity and few side effects which can be used as a medicine for preventing, treating, or preventing the relapse of neurological or immunological diseases. The problem is solved by providing an isolated RGMa binding protein which does not inhibit binding between RGMa and neogenin but neutralizes the neurite outgrowth inhibiting activity of RGMa, preferably by providing an anti-RGMa antibody which has complementarity determining regions having amino acid sequences of SEQ ID NOS: 30-35 or SEQ ID NOS: 36-40 in Sequence Listing, and SFG.

Abstract: A film having a metallic luster that is easier to manufacture and exhibits little degradation over time, an article having the film formed thereon, and a manufacturing method for the film having a metallic luster. The film, which has a metallic luster, is characterized by containing a thiophene polymer. The manufacturing method for the film which has a metallic luster is characterized by a thiophene being polymerized using an oxidizing agent and made into a solution containing the thiophene polymer, and then coating and drying the solution containing the thiophene polymer on an article. The article having the film, which has a metallic luster formed thereon, is characterized by containing a thiophene polymer.

Abstract: A manufacturing method for manufacturing a colored product, where using inkjet heads which are a plurality of color ink heads, and an inkjet head, which is a colorless ink head, a plurality of coloring regions are formed in an overlapping manner in a normal direction, a surface side colored region, which is a region located closest to the surface of the colored product is formed using at least the color ink ejected from any of the inkjet heads, and an inner colored region, which is a region located farther from the surface of the colored product than the surface side colored region is formed using at least the color ink ejected from any of the inkjet heads and the colorless ink ejected from the inkjet head.

Abstract: A thermoelectric conversion element includes: a thermoelectric conversion layer containing a thiophene polymer, in which a peak intensity of a diffraction angle (2?) of 7.9° is 5 times or more a peak intensity of a diffraction angle (2?) of 25.8° in an X-ray diffraction spectrum of the thermoelectric conversion layer.

Abstract: A composition for forming a metallic luster film, includes: a thiophene polymer, in which a total content of an Fe atom, a Cu atom, an Mn atom, a Cr atom, and a Ce atom in the composition for forming a metallic luster film is 1500 ppm or less with respect to the thiophene polymer.

Abstract: The present invention relates to a labeling technique which can facilitate the metabolism in the liver after administration to patients without the reduction in the antibody function, thereby reducing accumulation of radionuclides in an organ such as the liver, and provides a modified antibody containing an IgG antibody and an IgG-binding peptide bound to the IgG antibody. The IgG-binding peptide has an amino acid sequence consisting of 13 to 17 amino acid residues, such as GPDCAYH(Xaa1)GELVWCTFH wherein Xaa1 represents a lysine residue, a cysteine residue, an aspartic acid residue, a glutamic acid residue, 2-aminosuberic acid, or diaminopropionic acid, and a compound represented by the following formula (II-1) is linked at a position of the lysine residue via a modification linker to the N terminus of the IgG-binding peptide.

Abstract: The present invention aims to obtain an anti-repulsive guidance molecule a (RGMa) antibody having a high binding activity and few side effects which can be used as a medicine for preventing, treating, or preventing the relapse of neurological or immunological diseases. The problem is solved by providing an isolated RGMa binding protein which does not inhibit binding between RGMa and neogenin but neutralizes the neurite outgrowth inhibiting activity of RGMa, preferably by providing an anti-RGMa antibody which has complementarity determining regions having amino acid sequences of SEQ ID NOS: 30-35 or SEQ ID NOS: 36-40 in Sequence Listing, and SFG.

Abstract: A therapeutic agent for fibrosis, whose active ingredient is constituted by a glucosylceramide synthase inhibitor or lactosylceramide synthase inhibitor, or both, inhibits the nuclear translocation of phosphorylated Smad, thereby treating and preventing fibrosis.

Abstract: The present invention provides a target gene transcriptional repression inhibitor that can be designed in a sequence-specific manner, a composition containing the same, and use thereof. More specifically, the present invention provides a composition for use in inhibiting repression of gene expression by DNA methylation in a living subject, comprising pyrrole imidazole polyamide or a conjugate of pyrrole imidazole polyamide and a histone modifying enzyme inhibitor, wherein the pyrrole imidazole polyamide or the conjugate of pyrrole imidazole polyamide and a histone modifying enzyme inhibitor is designed so as to bind in a sequence-specific manner to a minor groove of promoter region DNA of the gene.

Abstract: Described are: [1] a compound represented by the formula (1), [2] a compound containing the compound according to [1] and a target molecule recognition element bonded thereto, [3] a metal complex compound containing one kind of a metal selected from a radioactive metal and a radioactive atom-labeled metal, and the compound according to [1] or [2], which is coordinated to the metal, [4] a drug for preparing a radiolabeled drug, containing the compound according to [1] or [2], [5] use of the compound according to [1] or [2], for producing a radiolabeled drug, [6] a radiolabeled drug containing the metal complex compound according to [3], and [7] a radiodiagnostic imaging agent containing the metal complex compound according to [3]:

Abstract: The invention provides a cationic lipid, a lipid membrane structure containing same, and use thereof. The cationic lipid is represented by the formula (1) wherein R1a, R1b, R2a, R2b, R3a, R3b, Xa, Xb, Ya, Yb, Za, and Zb are as defined in the specification.

Abstract: There is provided a biological information monitoring system for monitoring biological information of a subject on a bed, the system comprising: detectors which detect load of the subject; a center of gravity position calculating unit which acquires temporal variation of a center of gravity position of the subject based on the detected load; a body motion information determining unit which acquires information on body motion of the subject based on the acquired temporal variation; and a respiratory rate calculating unit which calculates a respiratory rate of the subject based on the acquired temporal variation and the information on the body motion of the subject. The body motion information includes information on large and small body motions of the subject, and the body motion information determining unit includes first and second body motion information determining units which determine the information on the large and small body motions of the subject, respectively.